Navigation Links
Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
Date:6/3/2008

PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 29th Annual Goldman Sachs Healthcare Conference at 1:25 p.m. Eastern Time on Tuesday, June 10, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the Bank of America 2008 Healthcare Conference
2. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
4. Medarex to Receive Milestone Payment from Novo Nordisk
5. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
7. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
8. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
9. Medarex Announces Completion of Sale of Shares in Genmab A/S
10. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
11. Medarex Announces Election of Marc Rubin as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track ... uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva ... , the relationship between insulin and other relevant biomarkers can be extensively studied ...
(Date:2/23/2017)... -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological ... Linda Marbán, Ph.D, president and chief executive officer, is scheduled ... Cowen and Company 37th Annual Health Care Conference Tuesday, ... MA 29th Annual ROTH Conference ... ET) Dana Point, CA ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):